Financial PerformanceLYRA reported earnings per share of $(0.18), surpassing the consensus expectation of $(0.22), indicating better than expected financial performance.
Regulatory ProgressLYRA aims to meet with the FDA to discuss a potential registrational path for LYR-210, which could provide valuable feedback.
Safety DataSupportive safety data from the ENLIGHTEN-1 study shows LYR-210 is well tolerated, even with repeat dosing over a 12-month treatment period.